4D pharma plc: 4D Pharma Announces U.S. SEC Declares Registration Statement Effective with Respect to the Issuance of 4D Pharma American Depositary Shares on NASDAQ finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
4D pharma plc: 4D Pharma to Participate in Upcoming Cantor Fitzgerald Microbiome Leaders Panel
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) a novel class of drug derived from the microbiome, today announces Duncan Peyton, Chief Executive Officer of 4D pharma, will participate in Cantor Fitzgerald s virtual panel, titled Microbiome Players with Guided Readouts in 2021, on Thursday, February 18, 2021 at 15:00 GMT (10:00 ET).
A webcast of the panel will be available via the Events section of the 4D pharma website at www.4dpharmaplc.com.
About 4D pharma
Founded in February 2014, 4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx, that rationall
Bone Therapeutics SA: Transparency notification received from CPH Banque – IT Business Net itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
1,600
Total number of shares with voting rights that can be issued following the exercise of the attributed warrants, and the conversion of the convertible bonds
804,315
(2)
(1) The total number of attributed warrants has increased by 99,832 warrants granted under the existing warrant plans.
(2)
232,887 shares can be issued in case all 232,887 attributed warrants are exercised.
571,428 shares can be issued in case all 1,600 convertible bonds outstanding, issued in the private placement on 6 May 2020, are converted into shares based on the predetermined conversion price of EUR 7.00.
About Bone Therapeutics
Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and other diseases. The Company has a, diversified portfolio of cell and biologic therapies at different stages ranging from pre-clinical programs in immunomodulation to mid-to-late stage clinical development for orthopedic condition